SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jayne, D
Right arrow Articles by Tyndall, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayne, D
Right arrow Articles by Tyndall, A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Autologous stem cell transplantation for systemic lupus erythematosus

D Jayne

Department of Medicine, Addenbrooke’s Hospital, Cambridge, UK, alan.tyndall{at}fps-basel.ch

A Tyndall

Department of Medicine, Addenbrooke’s Hospital, Cambridge, UK

Some patients with severe systemic lupus erythematosus do not respond to conventional immunosuppression or suffer severe side effects from such treatment. In order to explore the concept of immunoablationfollowed by haematopoieticstem cell transplantation(HSCT) or ‘rescue’, an internationalcollaboration has occurred over the past seven years. The European Group for Blood and Marrow Transplantation(EBMT) and The European League Against Rheumatism (EULAR) have analysed their collective phase I and II studies and found a remission rate (based on a reduction of the SLEDAI to < 3) in 66%, one-third of whom later relapsed to some degree. The most often used protocol was cyclophosphamide (CY) and G-CSF for mobilization and CY plus anti thymocyte globulin as conditioning. Procedure related mortality was 12% in this sick group of patients with major organ involvement. The North American, mostly single centre experience showed higher rates of remission and one procedure related death. Some relapse was also observed. Phase II studies designed to assess the role of post-HSCT maintenance therapy are being considered by the EBMT/EULAR group.

Key Words: autologous • stem cell • systemic lupus erythematosus • therapy • transplantation

Lupus, Vol. 13, No. 5, 359-365 (2004)
DOI: 10.1191/0961203304lu1027oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
S. Smith-Berdan, D. Gille, I. L. Weissman, and J. L. Christensen
Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells
Blood, August 15, 2007; 110(4): 1370 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
F-G Lehnhardt, C Scheid, U Holtik, L Burghaus, M Neveling, P Impekoven, A Ruger, M Hallek, A H Jacobs, and A Rubbert
Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction
Lupus, April 1, 2006; 15(4): 240 - 243.
[Abstract] [PDF]

Home page
 LupusHome page
H Tahir and D A Isenberg
Novel therapies in lupus nephritis
Lupus, January 1, 2005; 14(1): 77 - 82.
[Abstract] [PDF]


Advertisement